These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 32129697)

  • 1. Evaluation of
    Liao M; Jaw-Tsai S; Beltman J; Simmons AD; Harding TC; Xiao JJ
    Xenobiotica; 2020 Sep; 50(9):1032-1042. PubMed ID: 32129697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro cytochrome P450- and transporter-mediated drug interaction potential of 6β-hydroxy-21-desacetyl deflazacort-A major human metabolite of deflazacort.
    Ma J; Beers B; Manohar R; Roe S; Colacino JM; Kong R
    Pharmacol Res Perspect; 2021 Apr; 9(2):e00748. PubMed ID: 33749127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro evaluation of the inhibition and induction potential of olaparib, a potent poly(ADP-ribose) polymerase inhibitor, on cytochrome P450.
    McCormick A; Swaisland H; Reddy VP; Learoyd M; Scarfe G
    Xenobiotica; 2018 Jun; 48(6):555-564. PubMed ID: 28657402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
    Zurth C; Koskinen M; Fricke R; Prien O; Korjamo T; Graudenz K; Denner K; Bairlein M; von Bühler CJ; Wilkinson G; Gieschen H
    Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):747-759. PubMed ID: 31571146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of drug-drug interactions of CC-90001, a potent and selective inhibitor of c-Jun N-terminal kinase.
    Tong Z; Gaudy A; Tatosian D; Ramirez-Valle F; Liu H; Chen J; Hoffmann M; Surapaneni S
    Xenobiotica; 2021 Dec; 51(12):1416-1426. PubMed ID: 35000550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Assessment of the In Vitro Inhibition of Cytochrome P450 Enzymes, UDP-Glucuronosyltransferases, and Transporters by Phosphodiester- or Phosphorothioate-Linked Oligonucleotides.
    Kazmi F; Yerino P; McCoy C; Parkinson A; Buckley DB; Ogilvie BW
    Drug Metab Dispos; 2018 Aug; 46(8):1066-1074. PubMed ID: 29735754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor.
    Zhang H; Ou YC; Su D; Wang F; Wang L; Sahasranaman S; Tang Z
    Pharmacol Res Perspect; 2021 Dec; 9(6):e00870. PubMed ID: 34664792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro assessment of the roles of drug transporters in the disposition and drug-drug interaction potential of olaparib.
    McCormick A; Swaisland H
    Xenobiotica; 2017 Oct; 47(10):903-915. PubMed ID: 27684210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor.
    Chino Y; Hasegawa M; Fukasawa Y; Mano Y; Bando K; Miyata A; Nakai Y; Endo H; Yamaguchi JI
    Xenobiotica; 2017 Apr; 47(4):314-323. PubMed ID: 27324291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transport properties of valsartan, sacubitril and its active metabolite (LBQ657) as determinants of disposition.
    Hanna I; Alexander N; Crouthamel MH; Davis J; Natrillo A; Tran P; Vapurcuyan A; Zhu B
    Xenobiotica; 2018 Mar; 48(3):300-313. PubMed ID: 28281384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vitro Interaction of AB-FUBINACA with Human Cytochrome P450, UDP-Glucuronosyltransferase Enzymes and Drug Transporters.
    Kim S; Kim DK; Shin Y; Jeon JH; Song IS; Lee HS
    Molecules; 2020 Oct; 25(19):. PubMed ID: 33050066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1.
    Kimoto E; Vourvahis M; Scialis RJ; Eng H; Rodrigues AD; Varma MVS
    Drug Metab Dispos; 2019 May; 47(5):493-503. PubMed ID: 30862625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib.
    Liao M; Beltman J; Giordano H; Harding TC; Maloney L; Simmons AD; Xiao JJ
    Clin Pharmacokinet; 2022 Nov; 61(11):1477-1493. PubMed ID: 36107395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Drug-Drug Interactions of Rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp Substrates in Patients With an Advanced Solid Tumor.
    Xiao JJ; Nowak D; Ramlau R; Tomaszewska-Kiecana M; Wysocki PJ; Isaacson J; Beltman J; Nash E; Kaczanowski R; Arold G; Watkins S
    Clin Transl Sci; 2019 Jan; 12(1):58-65. PubMed ID: 30427584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro drug-drug interactions of budesonide: inhibition and induction of transporters and cytochrome P450 enzymes.
    Chen N; Cui D; Wang Q; Wen Z; Finkelman RD; Welty D
    Xenobiotica; 2018 Jun; 48(6):637-646. PubMed ID: 28730856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absorption, Metabolism, Distribution, and Excretion of Letermovir.
    Menzel K; Kothare P; McCrea JB; Chu X; Kropeit D
    Curr Drug Metab; 2021; 22(10):784-794. PubMed ID: 33622223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct Imaging of Drug Distribution and Target Engagement of the PARP Inhibitor Rucaparib.
    Kossatz S; Carney B; Farley C; Weber WA; Drain CM; Reiner T
    J Nucl Med; 2018 Aug; 59(8):1316-1320. PubMed ID: 29572258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699).
    Durmus S; Sparidans RW; van Esch A; Wagenaar E; Beijnen JH; Schinkel AH
    Pharm Res; 2015 Jan; 32(1):37-46. PubMed ID: 24962512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Use of Transporter Probe Drug Cocktails for the Assessment of Transporter-Based Drug-Drug Interactions in a Clinical Setting-Proposal of a Four Component Transporter Cocktail.
    Ebner T; Ishiguro N; Taub ME
    J Pharm Sci; 2015 Sep; 104(9):3220-8. PubMed ID: 25981193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam.
    Reese MJ; Bowers GD; Humphreys JE; Gould EP; Ford SL; Webster LO; Polli JW
    Xenobiotica; 2016; 46(5):445-56. PubMed ID: 26340566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.